Advanced Biomed Inc. (ADVB) Earnings Signals & AI Vibe Check

Latest Filing: 10-Q  |  Filed Feb 13, 2026

Cross-checked across multiple AI analysts and grounded in the latest SEC filing.

powered by: earningsVibe.ai

Question:
What is the latest filing signal for Advanced Biomed Inc.?
Answer:
Based on earningsVibe SuperAnalyst™ synthesis of the latest 10-Q, Advanced Biomed Inc.'s filing signal turned negative.
earningsVibe SuperAnalyst™ Verdict: TURNED NEGATIVE

Signal Performance — Stock Price Since Filing

30-Day Change
+13.12%
from filing date
60-Day Change
Pending
from filing date

Underlying analyst views from Perplexity, Gemini, Claude, and ChatGPT

PERPLEXITY
Continuing Negative
GEMINI
Turned Negative
CLAUDE
Turned Positive
CHATGPT
Turned Positive

Unlock the Full Filing Analysis

See full earningsSig™ and risksSig™ analysis across 5,000+ companies

Get Started Free →

No credit card required

Question:
What does Advanced Biomed Inc. actually do?
Answer:
Advanced Biomed Inc. is a holding company focused on developing and commercializing technologies for early cancer screening and diagnosis. Leveraging a proprietary microfluidic technology platform, the company integrates semiconductor and biotechnology to create advanced research tools and medical testing equipment. Its product pipeline includes devices for circulating tumor cell (CTC) detection and enrichment, such as A Pre, AC-1000, A CellScan, and A SCDrop, along with immunostaining kits and a 3D cell culture system. The company's strategy involves centralized R&D with localized market management, initially focusing on China, with plans for expansion into North America and Europe. Advanced Biomed aims to provide rapid, affordable assay products and services to assist in cancer treatment selection and patient prognosis.
Question:
What are Advanced Biomed Inc.'s revenue drivers?
Answer:
The company has not yet commenced sales of any products and does not expect revenue-generating products until regulatory approvals are obtained. Future revenue will be driven by the commercialization of its cancer detection and diagnostic products.

Cut through noisy SEC filings to find the signal faster

Source-grounded filing intelligence with one-click links back to the filing, so you can move faster and verify everything at the source.

Get Started Free →

No credit card required